MR1 and cancer: Using a genome-wide CRISPR/Cas9 screen, Andrews found that the TCR recognizes and destroys cancer-specific cells through the antigen-presenting molecule MR1 (MHC class I-associated protein 1) and does not recognise recognise non-cancer cells.